KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Idexx Laboratories (IDXX) over the last 17 years, with Sep 2025 value amounting to $208.2 million.

  • Idexx Laboratories' Cash & Equivalents fell 32.55% to $208.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $208.2 million, marking a year-over-year decrease of 32.55%. This contributed to the annual value of $288.3 million for FY2024, which is 36.50% down from last year.
  • Per Idexx Laboratories' latest filing, its Cash & Equivalents stood at $208.2 million for Q3 2025, which was up 26.47% from $164.6 million recorded in Q2 2025.
  • In the past 5 years, Idexx Laboratories' Cash & Equivalents registered a high of $453.9 million during Q4 2023, and its lowest value of $99.2 million during Q3 2022.
  • Moreover, its 3-year median value for Cash & Equivalents was $288.3 million (2024), whereas its average is $269.3 million.
  • Examining YoY changes over the last 5 years, Idexx Laboratories' Cash & Equivalents showed a top increase of 331.43% in 2021 and a maximum decrease of 62.37% in 2021.
  • Idexx Laboratories' Cash & Equivalents (Quarterly) stood at $144.5 million in 2021, then dropped by 22.09% to $112.5 million in 2022, then skyrocketed by 303.33% to $453.9 million in 2023, then slumped by 36.50% to $288.3 million in 2024, then crashed by 32.55% to $208.2 million in 2025.
  • Its Cash & Equivalents was $208.2 million in Q3 2025, compared to $164.6 million in Q2 2025 and $164.0 million in Q1 2025.